<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39404024</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Relative Effectiveness and Waning of a Third Dose of mRNA COVID-19 Vaccine in Medicare Beneficiaries Aged 65 Years and Older during the BA.1/BA.2 Omicron Period.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">jiae503</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiae503</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">We assessed the added benefit and waning effectiveness of a third COVID-19 vaccine dose (original formula) for preventing COVID-19-related outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We used Medicare claims data to conduct a retrospective cohort study in U.S. community-dwelling Medicare Fee-for-Service beneficiaries aged â‰¥65 years during the BA.1/BA.2 Omicron period (December 19, 2021 - March 26, 2022). We estimated relative vaccine effectiveness (RVE) of 3 versus 2 doses of mRNA COVID-19 vaccines using marginal structural Cox regression models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 8,135,020 eligible beneficiaries, 73.3% were 3-dose vaccinated by March 26, 2022. At 14-60 days since vaccination, a third dose provided significant added benefit against COVID-19-related hospitalization for Moderna (RVE: 77.2%; 95% confidence interval (CI): 76.0%, 78.4%) and Pfizer-BioNTech (RVE: 72.5%; 95% CI: 70.8%, 74.0%). Added benefit was lower &gt;120 days. For those with prior medically attended COVID-19 diagnoses, Pfizer-BioNTech provided an added benefit for 120 days, while Moderna provided some added benefit &gt;120 days. Added benefit for either vaccine was higher against death compared to less severe outcomes, which still decreased &gt;120 days.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A third dose COVID-19 vaccine provided significant added benefit against COVID-19-related hospitalization and death, even for beneficiaries with prior medically attended COVID-19 diagnoses. This added benefit decreased after 4 months.</AbstractText><CopyrightInformation>Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9332-6832</Identifier><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matuska</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Acumen LLC, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McEvoy</LastName><ForeName>Rowan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0009-0004-1074-6110</Identifier><AffiliationInfo><Affiliation>Acumen LLC, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izurieta</LastName><ForeName>Hector S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hervol</LastName><ForeName>Jessica Rose</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-8358-8000</Identifier><AffiliationInfo><Affiliation>Acumen LLC, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menis</LastName><ForeName>Mikhail</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindaas</LastName><ForeName>Arnstein</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0002-2568-3509</Identifier><AffiliationInfo><Affiliation>Acumen LLC, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steele</LastName><ForeName>Whitney R</ForeName><Initials>WR</Initials><Identifier Source="ORCID">0000-0001-7955-3115</Identifier><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chillarige</LastName><ForeName>Yoganand</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8020-6839</Identifier><AffiliationInfo><Affiliation>Acumen LLC, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wernecke</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9553-3122</Identifier><AffiliationInfo><Affiliation>Acumen LLC, Burlingame, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelman</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centers for Medicare &amp; Medicaid Services, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forshee</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BA.1/BA.2 Omicron Period</Keyword><Keyword MajorTopicYN="N">COVID-19-related hospitalizations</Keyword><Keyword MajorTopicYN="N">Medicare beneficiaries</Keyword><Keyword MajorTopicYN="N">U. S. older adults</Keyword><Keyword MajorTopicYN="N">added benefit</Keyword><Keyword MajorTopicYN="N">mRNA COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">relative vaccine effectiveness</Keyword><Keyword MajorTopicYN="N">waning effectiveness</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>7</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39404024</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiae503</ArticleId><ArticleId IdType="pii">7822280</ArticleId></ArticleIdList></PubmedData></PubmedArticle>